ImmunityBio to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary

ImmunityBio (NASDAQ: IBRX), an immunotherapy innovator, has announced its participation in the Jefferies London Healthcare Conference. The event is scheduled for November 19-21, 2024 at the Waldorf Hilton London. Company executives will engage in a fireside chat on Tuesday, November 19, 2024, at 2:30 PM GT.

Investors and interested parties can access a replay of the recorded presentation through the Events and Presentations section of ImmunityBio's website at https://ir.immunitybio.com/. The replay will be available for 90 days following the conference.

CULVER CITY, Calif.--(BUSINESS WIRE)-- Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that company executives will be participating in the Jefferies London Healthcare Conference, which is taking place November 19-21 at the Waldorf Hilton London.

Details of the presentation can be found below.

Jefferies London Healthcare Conference

Date:	Tuesday, November 19, 2024
Time:	2:30 PM GT
Format:	Fireside chat with ImmunityBio company executives

A replay of the recorded fireside presentation will be available through the Events and Presentations section of the ImmunityBio website at https://ir.immunitybio.com/ for 90 days.

About ImmunityBio

ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA^® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.

For more information, visit www.immunitybio.com and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding conference participation and timing, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA and use in cancer vaccines and across multiple tumor types, and ImmunityBio’s approved product and investigational agents as compared to existing treatment options, among others. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “is,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties related to the regulatory submission and review process, (ii) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (iii) whether clinical trials will result in registrational pathways and the risks and uncertainties regarding the regulatory submission, review and approval process, (iv) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (v) potential delays in product availability and regulatory approvals, (vi) ImmunityBio’s ability to retain and hire key personnel, (vii) ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (viii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (ix) ImmunityBio’s ability to successfully commercialize its approved product and product candidates, (x) ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xi) ImmunityBio’s ability to obtain, maintain, protect and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 19, 2024 and the Company’s Form 10-Q filed with the SEC on August 12, 2024, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241021229120/en/

Investors

Hemanth Ramaprakash, PhD, MBA

ImmunityBio, Inc.

+1 858-746-9289

Hemanth.Ramaprakash@ImmunityBio.com

Media

Sarah Singleton

ImmunityBio, Inc.

+1 415-290-8045

Sarah.Singleton@ImmunityBio.com

Source: ImmunityBio, Inc.

FAQ

When and where is ImmunityBio (IBRX) presenting at the Jefferies London Healthcare Conference?

ImmunityBio (IBRX) is presenting at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 2:30 PM GT. The conference is taking place at the Waldorf Hilton London from November 19-21, 2024.

What format will ImmunityBio's (IBRX) presentation take at the Jefferies London Healthcare Conference?

ImmunityBio's (IBRX) presentation at the Jefferies London Healthcare Conference will be in the format of a fireside chat with company executives.

How can investors access ImmunityBio's (IBRX) presentation from the Jefferies London Healthcare Conference?

Investors can access a replay of ImmunityBio's (IBRX) recorded presentation through the Events and Presentations section of the company's website at https://ir.immunitybio.com/ for 90 days following the conference.

What is the stock symbol for ImmunityBio mentioned in the press release?

The stock symbol for ImmunityBio mentioned in the press release is IBRX, traded on the NASDAQ stock exchange.